Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. As of May 6, 2025, the average one-year price target for ...

The projected annual revenue for Regeneron Pharmaceuticals is 14,197MM ... of the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial data ...

In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals ... and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of ...

There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals ... author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year ...

Regeneron Pharmaceuticals (NASDAQ:REGN) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology ...